RxDoctor Payments Data

Frances Batin, MD

Internal Medicine · Hemet, CANPI 1609898758

Payments from drug & device makers

$1,128in general payments, 2019–2025

Across 60 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$223
  • Novo Nordisk$155
  • Abbott$116
  • AstraZeneca$112
  • Corcept Therapeutics$97
  • Lilly USA, LLC$76
  • plus $350 from 15 others

What the payments were for

  • Food & beverage$1,128100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,128 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$49,296
Medicare patients
171
Services billed
546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide82$84,259
EliquisApixaban75$68,147
MounjaroTirzepatide34$49,284
JanuviaSitagliptin Phosphate34$46,078
JardianceEmpagliflozin32$33,919
TrulicityDulaglutide23$30,990
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$19,685
MyrbetriqMirabegron17$16,927
EntrestoSacubitril/Valsartan12$15,572
LinzessLinaclotide15$12,052
Breo ElliptaFluticasone/Vilanterol16$10,381
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$8,782
BelsomraSuvorexant20$8,385
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen326$7,120
Lantus SolostarInsulin Glargine,hum.Rec.Anlog54$5,519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$155$84,25982 claims
Lilly USA, LLCMounjaro, Trulicity$76$80,27457 claims
Boehringer IngelheimJardiance$24$33,91932 claims
GSKTrelegy Ellipta, Breo Ellipta$28$30,06633 claims
Astellas Pharma US IncMyrbetriq$13$16,92717 claims
AbbVieLinzess, Synthroid$14$13,76355 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Hemet

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →